Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507936 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT00507936 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 280 participants.
The verdict
NCT00507936, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.
Interventions
- DRUG Duloxetine
- DRUG placebo
- DRUG ABT-894
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507936
The ClinicalTrials.gov registry entry for NCT00507936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Duloxetine is the first listed.
NCT00507936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00507936 about?
NCT00507936 is a clinical study titled "Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain". This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 si...
What is the current status of trial NCT00507936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00507936?
The interventions under investigation include: Duloxetine (DRUG), placebo (DRUG), ABT-894 (DRUG).
Who is sponsoring clinical trial NCT00507936?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.